MDxHealth SA (MDXH) Stock Forecast & Price Target

MDxHealth is viewed positively because its refocused prostate cancer diagnostics franchise now looks cleaner, with Resolve wound down and the $10.4M Novitas claim off the books, reducing a meaningful liability overhang and sharpening commercial execution. Growth should be supported by favorable urology industry tailwinds, the expanding role of GPS under NCCN guidance, and the acquired ExoDx test, which was bought for $15m and is expected to contribute $20m+ of revenue in 2026, while consensus 2027 revenue is cited at $127M. The investment case is further strengthened by pro-forma cash of about $39 million, expectations for positive adjusted EBITDA in Q4’26, and a path to roughly 20% adjusted EBITDA margin by exiting 2028.

MDxHealth is facing a weakened fundamental outlook after pre-announcing Q3 revenue of $22.7M, down 5% year over year and 17% sequentially, while tissue volumes of 11,232 and liquid-based test volumes of 11,792 both missed expectations. The miss, attributed to unexpected sales rep turnover after winding down Resolve UTI earlier in 2026, raises execution concerns just as management suspended 2026 revenue guidance of $110M-$115M, suggesting visibility into growth has deteriorated. Balance-sheet pressure also adds to the bearish case, with only $31.7M of cash and additional contingent payments of $18M in 2027 and $21M in 2028, limiting flexibility if commercial weakness persists.